NR566 Final Exam Study Guide
NR566 Final Exam Study Guide Week 5 - Prevention of osteoporosis with hormone replacement therapy Tara (p.433) Hormone therapy reduces postmenopausal bone loss and thereby decreases the risk for osteoporosis and related fractures. Therapy is lifelong and the risk for harm is increased. Hormone therapy should only be considered for women with significant risk for osteoporosis, and only when that risk outweighs the risks of hormone therapy. Meds are: raloxifene (Evista), bisphosphonates (e.g., alendronate {Fosamax}), calcitonin (Miacalin), and teriparatide (Forteo). Encourage patients to prevent bone loss by ensuring adequate intake of calcium and Vit D, performing regular weight-bearing exercises, and avoiding smoking and excessive alcohol use. - When and when not to use progestin for hormone replacement therapy and why Tara (p.430-432) When: Menopausal hormone therapy Why: The primary noncontraceptive use of progestins is to counteract the adverse effects of estrogen on the endometrium in women undergoing menopausal HT. When: Dysfunctional uterine bleeding Why: Heavy irregular bleeding that occurs when progesterone levels are insufficient to
Información del documento
- Subido en
- 31 de agosto de 2022
- Número de páginas
- 32
- Escrito en
- 2022/2023
- Tipo
- Examen
- Contiene
- Preguntas y respuestas